Ginkgo Bioworks Shares Decline Post Q4 2025 Financial Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy DNA?
Source: Benzinga
- Strategic Shift: In its Q4 2025 financial report, Ginkgo Bioworks announced a pivot towards robotics and AI, with CEO Jason Kelly highlighting collaborations with the Department of Energy and OpenAI, aiming to enhance the company's competitiveness in emerging technologies.
- Divestiture Plan: The company plans to sell its biosecurity business for a minority stake to a consortium of investors, with the transaction expected to close in the first half of 2026, allowing Ginkgo to concentrate resources on its autonomous labs initiative and enhance core business growth potential.
- Market Reaction: Following the financial report, Ginkgo Bioworks shares fell by 24.7%, currently trading at $7.31, which is 18.13% and 12.5% below its 20-day and 100-day simple moving averages, indicating market concerns regarding the company's future prospects.
- Analyst Ratings: While William Blair analysts believe the company is moving in the right direction, they maintain an Underperform rating, citing challenges due to low visibility and transparency, with an average price target of $169.73.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNA
Wall Street analysts forecast DNA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.480
Low
12.00
Averages
12.00
High
12.00
Current: 5.480
Low
12.00
Averages
12.00
High
12.00
About DNA
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elon Musk Could Rebuild Jurassic Park
- Musk's Wealth: Billionaire Elon Musk possesses enough wealth to buy every MLB, NBA, NFL, and NHL team, showcasing his immense influence in the global economy and potential for funding ambitious projects.
- Jurassic Park Franchise Success: Comcast's Jurassic Park franchise has grossed over $2.6 billion domestically, with the original 1993 film earning $357.1 million, highlighting its strong appeal in the entertainment industry.
- Biotech Advancements: Companies like Ginkgo Bioworks and Colossal Biosciences are working on de-extinction, with Ginkgo successfully reviving scents from extinct plants and Colossal bringing back the Dire Wolf in 2025, demonstrating the potential of modern biotechnology.
- Musk's Inspiration: Musk was inspired by X Head of Product Nikita Bier's post about Jurassic Park, expressing interest in reviving dinosaurs, although Colossal states there is currently no dinosaur DNA, reflecting the complex relationship between science and commercial aspirations.
See More
Ginkgo Bioworks Stock Falls After Earnings Miss and Shift to Robotics Focus
- Earnings Miss: Ginkgo Bioworks' recent earnings report revealed a revenue miss, leading to a stock price decline that reflects market concerns about its future growth potential.
- Sales Decline: The reported sales figures fell short of analyst expectations, indicating that weak customer demand in the current market environment could hinder revenue growth.
- Strategic Shift: Ginkgo Bioworks is transitioning towards autonomous labs and robotics, aiming to enhance operational efficiency to tackle market challenges, although this shift may increase costs in the short term.
- Market Reaction: Investor response to the company's strategic shift has been cautious, as the stock price drop suggests a lack of confidence in the new strategy, which could impact future financing and investor relations.
See More
Ginkgo Bioworks Shares Decline Post Q4 2025 Financial Report
- Strategic Shift: In its Q4 2025 financial report, Ginkgo Bioworks announced a pivot towards robotics and AI, with CEO Jason Kelly highlighting collaborations with the Department of Energy and OpenAI, aiming to enhance the company's competitiveness in emerging technologies.
- Divestiture Plan: The company plans to sell its biosecurity business for a minority stake to a consortium of investors, with the transaction expected to close in the first half of 2026, allowing Ginkgo to concentrate resources on its autonomous labs initiative and enhance core business growth potential.
- Market Reaction: Following the financial report, Ginkgo Bioworks shares fell by 24.7%, currently trading at $7.31, which is 18.13% and 12.5% below its 20-day and 100-day simple moving averages, indicating market concerns regarding the company's future prospects.
- Analyst Ratings: While William Blair analysts believe the company is moving in the right direction, they maintain an Underperform rating, citing challenges due to low visibility and transparency, with an average price target of $169.73.
See More
Applied Optoelectronics Reports Strong Q4, Shares Surge
- Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
- Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
- Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
- Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
See More
Ginkgo Bioworks Updates on Q4 2025 Financial Results
- Financial Overview: Ginkgo Bioworks reported a net loss of $312.8 million for Q4 2025, an improvement from $547 million in Q4 2024, indicating efforts in cost control and operational optimization, although the overall financial situation remains challenging.
- Biosecurity Business Divestiture: The company announced the sale of its biosecurity business to a consortium of investors, expected to complete in the first half of 2026, allowing the biosecurity unit to operate independently, enhancing its flexibility and resource acquisition to accelerate growth.
- Focus on Autonomous Labs: Ginkgo plans to concentrate investments in the autonomous labs sector, with CEO Jason Kelly highlighting the rising interest in robotics and AI, which is expected to significantly enhance the company's value in laboratory research and drive future revenue growth.
- Future Outlook and Strategy: Ginkgo anticipates continued challenges in 2026, despite plans to optimize resource allocation through the divestiture of the biosecurity business, focusing on investments in autonomous labs to achieve long-term growth objectives.
See More
Ginkgo Bioworks Reports Q4 and Full Year 2025 Financial Results
- Revenue Decline: Ginkgo reported total revenue of $33 million for Q4 2025, a 24% decrease year-over-year, primarily due to shifts in customer demographics and restructuring, indicating pressure in market competitiveness.
- Cell Engineering Revenue: The cell engineering segment generated $26 million in Q4, down 26% from the previous year, highlighting challenges faced during the company's transition, which may impact future R&D investments and market share.
- Biosecurity Business Divestiture: Ginkgo announced the sale of its biosecurity business to a consortium of investors, expected to close in the first half of 2026, allowing the biosecurity unit to operate independently and enhancing its growth potential while enabling Ginkgo to focus resources on its autonomous labs business.
- Cash Position: As of December 31, 2025, Ginkgo held $423 million in cash and cash equivalents, providing a strong financial buffer despite ongoing losses, which supports its strategic investments in the biotechnology sector.
See More
Elon Musk Could Rebuild Jurassic Park
- Musk's Wealth: Billionaire Elon Musk possesses enough wealth to buy every MLB, NBA, NFL, and NHL team, showcasing his immense influence in the global economy and potential for funding ambitious projects.
- Jurassic Park Franchise Success: Comcast's Jurassic Park franchise has grossed over $2.6 billion domestically, with the original 1993 film earning $357.1 million, highlighting its strong appeal in the entertainment industry.
- Biotech Advancements: Companies like Ginkgo Bioworks and Colossal Biosciences are working on de-extinction, with Ginkgo successfully reviving scents from extinct plants and Colossal bringing back the Dire Wolf in 2025, demonstrating the potential of modern biotechnology.
- Musk's Inspiration: Musk was inspired by X Head of Product Nikita Bier's post about Jurassic Park, expressing interest in reviving dinosaurs, although Colossal states there is currently no dinosaur DNA, reflecting the complex relationship between science and commercial aspirations.
See More
Ginkgo Bioworks Stock Falls After Earnings Miss and Shift to Robotics Focus
- Earnings Miss: Ginkgo Bioworks' recent earnings report revealed a revenue miss, leading to a stock price decline that reflects market concerns about its future growth potential.
- Sales Decline: The reported sales figures fell short of analyst expectations, indicating that weak customer demand in the current market environment could hinder revenue growth.
- Strategic Shift: Ginkgo Bioworks is transitioning towards autonomous labs and robotics, aiming to enhance operational efficiency to tackle market challenges, although this shift may increase costs in the short term.
- Market Reaction: Investor response to the company's strategic shift has been cautious, as the stock price drop suggests a lack of confidence in the new strategy, which could impact future financing and investor relations.
See More
Ginkgo Bioworks Shares Decline Post Q4 2025 Financial Report
- Strategic Shift: In its Q4 2025 financial report, Ginkgo Bioworks announced a pivot towards robotics and AI, with CEO Jason Kelly highlighting collaborations with the Department of Energy and OpenAI, aiming to enhance the company's competitiveness in emerging technologies.
- Divestiture Plan: The company plans to sell its biosecurity business for a minority stake to a consortium of investors, with the transaction expected to close in the first half of 2026, allowing Ginkgo to concentrate resources on its autonomous labs initiative and enhance core business growth potential.
- Market Reaction: Following the financial report, Ginkgo Bioworks shares fell by 24.7%, currently trading at $7.31, which is 18.13% and 12.5% below its 20-day and 100-day simple moving averages, indicating market concerns regarding the company's future prospects.
- Analyst Ratings: While William Blair analysts believe the company is moving in the right direction, they maintain an Underperform rating, citing challenges due to low visibility and transparency, with an average price target of $169.73.
See More
Applied Optoelectronics Reports Strong Q4, Shares Surge
- Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
- Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
- Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
- Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
See More
Ginkgo Bioworks Updates on Q4 2025 Financial Results
- Financial Overview: Ginkgo Bioworks reported a net loss of $312.8 million for Q4 2025, an improvement from $547 million in Q4 2024, indicating efforts in cost control and operational optimization, although the overall financial situation remains challenging.
- Biosecurity Business Divestiture: The company announced the sale of its biosecurity business to a consortium of investors, expected to complete in the first half of 2026, allowing the biosecurity unit to operate independently, enhancing its flexibility and resource acquisition to accelerate growth.
- Focus on Autonomous Labs: Ginkgo plans to concentrate investments in the autonomous labs sector, with CEO Jason Kelly highlighting the rising interest in robotics and AI, which is expected to significantly enhance the company's value in laboratory research and drive future revenue growth.
- Future Outlook and Strategy: Ginkgo anticipates continued challenges in 2026, despite plans to optimize resource allocation through the divestiture of the biosecurity business, focusing on investments in autonomous labs to achieve long-term growth objectives.
See More
Ginkgo Bioworks Reports Q4 and Full Year 2025 Financial Results
- Revenue Decline: Ginkgo reported total revenue of $33 million for Q4 2025, a 24% decrease year-over-year, primarily due to shifts in customer demographics and restructuring, indicating pressure in market competitiveness.
- Cell Engineering Revenue: The cell engineering segment generated $26 million in Q4, down 26% from the previous year, highlighting challenges faced during the company's transition, which may impact future R&D investments and market share.
- Biosecurity Business Divestiture: Ginkgo announced the sale of its biosecurity business to a consortium of investors, expected to close in the first half of 2026, allowing the biosecurity unit to operate independently and enhancing its growth potential while enabling Ginkgo to focus resources on its autonomous labs business.
- Cash Position: As of December 31, 2025, Ginkgo held $423 million in cash and cash equivalents, providing a strong financial buffer despite ongoing losses, which supports its strategic investments in the biotechnology sector.
See More
